E
RLMD icon

Ergoteles’s Relmada Therapeutics RLMD Stock Holding History

Ergoteles’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-27,100
Closed -$66.7K – 676
2023
Q2 		$66.7K Buy
+27,100
New +$74.9K ﹤0.01% 940
2022
Q1 		– Sell
-91,500
Closed -$2.06M – 1578
2021
Q4 		$2.06M Buy
+91,500
New +$2.03M 0.08% 252

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ergoteles's RLMD Position: Q3 2023 in Review

Ergoteles sold out of Relmada Therapeutics (RLMD) in Q3 2023, closing a stake of 27,100 shares — an estimated $66.7K sold.

Ergoteles first reported a position in RLMD in Q4 2021 and held it in 2 quarters. The position peaked at $2.06M in Q4 2021. 87 funds tracked by Wall St. Rank hold RLMD as of Q3 2023.

  • Ergoteles reported no remaining Relmada Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 27,100 Relmada Therapeutics shares in Q3 2023, an estimated $66.7K.
  • Ergoteles first reported a position in Relmada Therapeutics in Q4 2021 and held it in 2 quarters.
  • Ergoteles's Relmada Therapeutics position peaked at $2.06M in Q4 2021.
  • 87 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.